Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep680 | Female Reproduction | ECE2016

Validation of the Estradiol III assay (Roche) in the ovulatory phase

Laskewitz Anke , Homminga Irene , Wagenmakers Lucie , Kobold Anneke Muller

Introduction: Estradiol is an important parameter in the evaluation of female fertility. Moreover, the measurement estradiol is essential in determining the right moment for oocyte retrieval in modified natural cycle IVF (MNC-IVF). Estradiol is measured by an immunochemical method and a change between immunoassays usually comes with a change in reference values due to differences in antibodies used and the lack of harmonization. In our hospital we changed in 2014 from the Auto...

ea0028s5.2 | Sprint or marathon: muscling in on the Olympics | SFEBES2012

Exercise effects on fat metabolism and insulin sensitivity in human muscle

Wagenmakers Anton , Shepherd Sam , van Loon Luc , Shaw Christopher

There is an accumulating amount of evidence that the metabolic adaptations to endurance exercise that result in increased intramuscular triglyceride (IMTG) stores and IMTG oxidation during exercise, also exert a protective effect on muscle insulin sensitivity. This seems to be a contradiction (known as the athlete's paradox) as large IMTG stores in sedentary and obese individuals coexist with high levels of fatty acid (FA) metabolites (specifically long-chain acylCoA, DAG and ...

ea0026p39 | Adrenal cortex | ECE2011

Quality of life in patients in long-term remission of Cushing’s syndrome is impaired, regardless of etiology, treatment strategy or remaining hormonal deficiencies

Wagenmakers M , Netea-Maier R , Dekkers T , den Heijer M , Hermus A

Background: Impaired health related quality of life (QOL) in patients in long-term remission of Cushing’s syndrome (CS) has previously been reported. However, the major determinants of the impaired QOL have not yet been established.Aim: To investigate QOL of patients in long-term remission of CS treated in our hospital (1969–2007) and to investigate the influence of the etiology of CS, treatment strategy, coexistent hypopituitarism and glucocor...

ea0019oc18 | Cardiovascular metabolism | SFEBES2009

Non alcoholic fatty liver disease is associated with increased 5α-reductase expression and activity and consequent HPA-axis activation

Ahmed A , Tomlinson J , Dowman J , Newsome P , Elias E , Wagenmakers A , Stewart P

Non alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. The potential role of glucocorticoids (GC) in the pathogenesis of NAFLD, is highlighted by patients with GC excess, Cushing’s syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although in most cases of NAFLD, circulating cortisol levels are normal, hepatic cortisol availability is controlled by enzymes that regenerate cortisol from inacti...

ea0037gp.04.01 | Steroids | ECE2015

Dual 5α-reductase inhibition causes hepatic lipid accumulation in man

Hazlehurst Jonathan , Oprescu Andrei , Nikolaou Nikolaos , Grinbergs Annabel , Davies Nigel , Flintham Robert , Hughes Beverley , Taylor Angela , Yu Jinglei , Wagenmakers Anton , Tomlinson Jeremy

5α reductases 1 and 2 (SRD5A1 and SRD5A2) metabolise cortisol into inactive 5α-dihydrocortisol contributing to the regulation of cortisol availability in addition to their established role in the generation of dihydrotestosterone from testosterone. Dutasteride and finasteride are commonly prescribed to patients with benign prostatic hyperplasia but their potential metabolic effects have only recently been identified. Dutasteride inhibits both SRD5A1and SRD5A2 whilst ...

ea0021oc1.8 | Diabetes and metabolism | SFEBES2009

Cortisol metabolism and hepatic expression of 11β-hydroxysteroid dehydrogenase type 1 in patients with non-alcoholic fatty liver disease

Ahmed Adeeba , Brady Theresa , Bailey Claire , Guest Phillip , Wagenmakers Anton , Newsome Phillip , Hubscher Stephan , Elias Elwyn , Adams David , Tomlinson Jeremy , Stewart Paul

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. The role of glucocorticoids (GC) in its pathogenesis, is highlighted in patients with GC excess, Cushing’s syndrome, who develop central adiposity, insulin resistance and in 20% of cases, NAFLD. Although circulating cortisol levels are normal in patients with NAFLD, hepatic cortisol availability is controlled by enzymes that regenerate cortisol from inactive cortisone (11&#94...

ea0056oc13.1 | The curious case of growth hormone | ECE2018

Postoperative use of somatostatin analogs and mortality in patients with acromegaly

Postma Mark R , Wolters Thalijn LC , van den Berg Gerrit , van Herwaarden Antonius E , Kobold Anneke C Muller , Sluiter Wim J , Wagenmakers Margreet A , van den Bergh Alfons CM , Wolffenbuttel Bruce HR , Hermus Ad RMM , Netea-Maier Romana T , van Beek Andre P

Objective: To assess the effect of somatostatin analogs (SSTA) on mortality in relation to metabolic control of acromegaly after pituitary surgery.Design: A retrospective study in two large tertiary referral centers in The Netherlands.Patients and methods: Three hundred and nineteen patients with acromegaly in whom pituitary surgery was performed as primary therapy between January 1980 and July 2017 were included (total follow-up: ...